AtriCure (ATRC) : Dafna Capital Management scooped up 500 additional shares in AtriCure during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 488,446 shares of AtriCure which is valued at $7,561,144.AtriCure makes up approximately 5.97% of Dafna Capital Management’s portfolio.
Other Hedge Funds, Including , Rhumbline Advisers boosted its stake in ATRC in the latest quarter, The investment management firm added 4,444 additional shares and now holds a total of 36,132 shares of AtriCure which is valued at $559,323.Blackrock Fund Advisors boosted its stake in ATRC in the latest quarter, The investment management firm added 87,089 additional shares and now holds a total of 817,634 shares of AtriCure which is valued at $12,656,974.
AtriCure opened for trading at $15.45 and hit $15.58 on the upside on Thursday, eventually ending the session at $15.5, with a gain of 0.71% or 0.11 points. The heightened volatility saw the trading volume jump to 1,97,002 shares. Company has a market cap of $515 M.
On the company’s financial health, AtriCure reported $-0.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.30. The company had revenue of $39.70 million for the quarter, compared to analysts expectations of $39.84 million. The company’s revenue was up 21.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.18 EPS.
Many Wall Street Analysts have commented on AtriCure. AtriCure was Resumed by JMP Securities to “Mkt Outperform” on Jun 30, 2016.
AtriCure Inc. is a medical device company providing atrial fibrillation (Afib) solutions. The Company has three primary product lines for cardiac tissue ablation and a product line for left atrial appendage exclusion. The Company’s Isolator Synergy System which includes its Isolator Synergy clamps generator and switchbox is used for the treatment of persistent and long-standing persistent Afib in patients who are undergoing open concomitant coronary artery bypass grafting and valve replacement or repair. The cryoICE cryosurgery product line offers a range of both single use and reusable cryoablation devices. The AtriClip Left Atrial Appendage Exclusion System is designed to occlude the heart’s left atrial appendage (LAA). Its radiofrequency (RF) ablation products are indicated for the ablation of cardiac tissue. The Company sells enabling technologies including its Lumitip dissectors and Endoscopic Technologies Inc.’s (Estech) line of reusable cardiac surgery instruments.